Skip to main content

Table 1 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in Norway.

From: Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

Week

45

46

47

48

49

50

51

52

53

Vaccinated population

No of cases

1

14

19

17

2

1

0

1

3

Population

32,766

266,278

501,115

698,006

873,629

1,105,763

1,397,506

1,675,354

1,891,980

Incidence(per 100,000)

3.05

5.26

3.79

2.44

0.23

0.09

0.00

0.06

0.16

Unvaccinated population

No of cases

2579

1612

866

453

187

84

34

16

12

Population

4,811,608

4,575,516

4,339,053

4,141,277

3,965,184

3,732,861

3,441,033

3,163,151

2,946,508

Incidence(per 100,000)

53.60

35.23

19.96

10.94

3.72

2.25

0.99

0.51

0.41

Vaccine effectiveness

Point estimate

94%

85%

81%

77%

95%

96%

100%

88%

61%

95% confidence interval

60%-99%

75%-90%

70%-88%

64%-86%

64%-99%

71%-99%

-

11%-92%

-37%-89%

  1. Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 45-53, 2009) of the influenza pandemic in Norway Vaccinees were considered immune 15 days and later after vaccination.